# Mesalazine

## MezaVant XL 1200mg prolonged release

##### 

| TAH Drug Code      | [OMEZA](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMEZA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of moderately active ulcerative colitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | 2.4 to 4.8g (2 to 4 tablets) QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | U.S. labeling: Hypersensitivity to mesalamine, aminosalicylates, salicylates, or any component of the formulation (including suppository vehicle of vegetable fatty acid esters) Canadian labeling: Hypersensitivity to mesalamine, salicylates, or any component of the formulation; severe renal impairment (GFR <30 mL/minute/1.73 m2); severe hepatic impairment Additional contraindications per specific Canadian product labeling: Existing gastric or duodenal ulcer, urinary tract obstruction, use in children <2 years of age (Asacol, Asacol 800, Mesasal, Pentasa, Salofalk); hemorrhagic diathesis (Mesasal); patients unable to swallow intact tablet (Asacol, Asacol 800); renal parenchymal disease (Pentasa) |
| Adverse Effects    | >10%: Central nervous system: Headache (2% to 35%), pain (?14%) Gastrointestinal: Abdominal pain (1% to 18%), eructation (16%), nausea (3% to 13%) Respiratory: Pharyngitis (11%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Pregnancy          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

